Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Tissue Regenix Group says 'maintaining level of sales is true testament to demand of our products'

Tissue Regenix Group says 'maintaining level of sales is true testament to demand of our products'

Tissue Regenix Group PLC's (LON:TRX) Daniel Lee talks to Proactive London about his experience in the sector, his new appointment as CEO as well the firm's performance for 2020.

In a trading update for the year to December 31, Lee says the revenues for the year will be £12.8mln, in line with the prior-year figure of £13mln despite the impact of the pandemic.

The regenerative medical devices specialist has also highlighted their cash position of £9.5mln following a fundraising in June.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK